Cryolipolysis for safe and effective inner thigh fat reduction
Background and Objectives While cryolipolysis initially received FDA clearance for fat reduction in the abdomen and flanks, there was significant interest in non‐surgical fat reduction for other sites, such as the inner and outer thighs. This article reports the results of an inner thigh study which...
Saved in:
Published in | Lasers in surgery and medicine Vol. 47; no. 2; pp. 120 - 127 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.02.2015
Wiley Subscription Services, Inc John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
ISSN | 0196-8092 1096-9101 1096-9101 |
DOI | 10.1002/lsm.22320 |
Cover
Summary: | Background and Objectives
While cryolipolysis initially received FDA clearance for fat reduction in the abdomen and flanks, there was significant interest in non‐surgical fat reduction for other sites, such as the inner and outer thighs. This article reports the results of an inner thigh study which contributed to FDA clearance of cryolipolysis for treatment of thighs.
Study Design/Material and Methods
A flat cup vacuum applicator (CoolFit applicator, CoolSculpting System) was used to treat 45 subjects bilaterally in the inner thighs. Single cycle treatments were delivered at Cooling Intensity Factor (CIF) 41.6 for 60 minutes followed by 2 minutes of manual massage. Follow‐up visits were conducted at 8 and 16 weeks. Efficacy was assessed by ultrasound imaging, circumference measurements, and photographs. Safety was assessed by monitoring adverse events. Patient satisfaction was evaluated by questionnaire.
Results
Data is presented for n = 42 patients that completed the 16 week study follow‐up and maintained their weight within 5 lbs. of baseline. Independent photo review from three blinded physicians found 91% correct identification of baseline clinical photographs. Ultrasound data indicate fat layer reduction of 2.8 mm. Circumferential measurements indicate mean reduction of 0.9 cm. Patient questionnaires reveal 93% were satisfied with the CoolSculpting procedure; 84% noticed visible fat reduction; 89% would recommend to a friend; and 91% were likely to have a second treatment. There were no device‐ or procedure‐related serious adverse events.
Conclusion
The CoolFit flat cup vacuum applicator was found to deliver safe and effective cryolipolysis treatment to reduce inner thigh fat. Completed 16‐week data from 42 subjects show 2.8 mm reduction in fat thickness and 0.9 cm reduction in circumference. Assessment of clinical photographs found 91% correct identification of baseline images. The results of this prospective, multi‐center, interventional clinical study contributed to FDA clearance of cryolipolysis for treatment of thighs in April 2014. Lasers Surg. Med. 47:120–127, 2015. © 2015 The Authors. Lasers in Surgery and Medicine Published by Wiley Periodicals, Inc. |
---|---|
Bibliography: | ark:/67375/WNG-B9J5RWXZ-F istex:6DE53E7755AA69B2344F14C9BC17382C87D4F72C ArticleID:LSM22320 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 Disclosures: Dr. Zelickson is on the medical advisory boards for Zeltiq, Lumenis, Candela, Ulthera, and Eleme; received research grants from Sciton, Candela, Palomar, Syneron, Silk'n, Valeant, Lumenis, Ulthera, Zeltiq, Canfield, and Wave Rx. Dr. Burns is on the medical advisory boards for Zeltiq, Ulthera, Cynosure, Myoscience, and Thermi‐Aesthetics; receives honoraria from Valeant, Sciton, Zeltiq, and Ulthera; receives funding through research grants from Valeant, Zeltiq, and Ulthera; owns stock and/or stock options in Zeltiq; and receives equipment discounts or loans from Palomar, Cynosure, Sciton, Zimmer, Zeltiq, and Cutera. Dr. Kilmer is on the medical advisory boards for Candela/Syneron, Living Proof/Strateris, Lumenis, Lutronics, and Zeltiq and receives research support from Candela/Syneron, Living Proof/Strateris, Lumenis, Lutronics, Zeltiq, Allergan, Cutera, Cynosure/Palomar, and Valeant. |
ISSN: | 0196-8092 1096-9101 1096-9101 |
DOI: | 10.1002/lsm.22320 |